CSI Market
Sign In | Register

Addex Therapeutics Ltd (ADXN) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access ADXN Annual Income Statement →
The data below summarizes Addex Therapeutics Ltd's income statement results from Dec 31 2024 to Dec 31 2025, enabling period-by-period comparison of operating performance.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
Q4 2025 		0 0 0 (Dec 31 2024)
Revenues
Revenue From Contracts With Customers0.03
Total Revenue0.03
Costs & Expenses
Gross Profit0.03
Selling, Administration, Marketing2.32
Research and Development Expense0.67
Other Operating Expense / -Income-0.14
Total operating costs including COS2.84
Operating income / -loss-2.81
Net Interest (-)Expense / Income0.00
Other loss / -income0.02
Total costs & expenses6.87
Income & Taxes
Income / -loss before income taxes-6.84
Income after income taxes-6.73
Net income / -loss of other equity0.11
Income / -loss from continuing operations-6.73
Net income / -loss-6.73
Income / -loss to shareholder-6.73
EBIT-6.84
EBITD-6.83
EBITDA-6.83
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Basic shares outstanding (Mill. of Units)0.00
Diluted Net EPS0.00
Diluted average shares (Mill. of Units)0.00
4 historic quarters locked

Sign in to unlock the full Addex Therapeutics Ltd income statement history.

Sign In Create Free Account

About ADXN Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.